Skip to main content

Table 2 Clinical benefit and progression-free survival: multivariate analyses in patients with molecular alterations

From: Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

Clinical Benefit (CR + PR + SD ≥ 6 months), evaluable for response (N = 1256)
Risk Factor (vs. other)OR95% CIp
PI3K/AKT/mTOR alterations.73.53–1.02.06
Liver metastases.54.39–.76< .001
LDH > ULN.61.43–.86.004
Performance status > 1.50.24–1.02.06
Albumin < ULN.68.37–1.25.21
Type of therapy added
 Non-matched therapy.67.49–.90.01
 PI3K/AKT/mTOR alterations.67.48–.94.02
 Liver metastases.55.39–.77< .001
 LDH > ULN.63.45–.89.01
 Performance status > 1.51.25–1.05.07
 Albumin < ULN.69.97–1.27.23
Progression-Free Survival (n = 1307)
Risk Factor (vs. other)HR95% CIp
PI3K/AKT/mTOR alterations1.11.98–1.27.09
Liver metastases1.451.27–1.64< .001
LDH > ULN1.501.31–1.70< .001
Performance status > 11.571.24–1.99< .001
Albumin < ULN1.351.09–1.67.01
Platelets > ULN1.14.85–1.53.39
Age ≥ 60 years.97.86–1.09.57
Type of therapy added
 Non-matched therapy1.391.23–1.58< .001
 PI3K/AKT/mTOR alterations1.161.02–1.32.02
 Liver metastases1.431.26–1.62< .001
 LDH > ULN1.441.26–1.64< .001
 Performance status > 11.541.22–1.95< .001
 Albumin < ULN1.311.06–1.62.01
 Platelet count > ULN1.09.81–1.46.59
 Age ≥ 60 years.95.84–1.07.37
  1. Abbreviations: CI confidence interval, CR complete response, HR hazard ratio, LDH lactate dehydrogenase, PR partial response, SD stable disease, ULN upper limit of normal